CTLA4 and colorectal carcinoma: This provides a good indication that a significant proportion of the CYT-high CRC patients, indeed, belong to a previously unappreciated cohort that could benefit from immune checkpoint inhibition therapy using anti-PD-1 alone or in combination with anti-CTLA-4 monoclonal antibodies.